Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rutherford

Showing results (551-560 of 603) with videos related to

Pageof 61
Sort By:
British Journal of Cancer|August 12, 2010
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinomaE Cocco, Z Hu, C E Richter, et al.
International Journal of Cancer|August 30, 2021
Comparison of liver cancer incidence and survival by subtypes across seven high-income countriesMark J Rutherford, Melina Arnold, Aude Bardot, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|June 22, 2021
Case-ascertainment of acute myocardial infarction hospitalizations in cancer patients: a cohort study using English linked electronic health dataBriana Coles, Lucy Teece, Clive Weston, et al.
Clinical & Experimental Metastasis|July 5, 2011
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factorEmiliano Cocco, Joyce Varughese, Natalia Buza, et al.
Neurobiology of Aging|May 3, 2013
Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUSThomas A Ravenscroft, Matt C Baker, Nicola J Rutherford, et al.
British Journal of Cancer|November 19, 2009
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinomaK El-Sahwi, S Bellone, E Cocco, et al.
Molecular Cancer Therapeutics|January 8, 2010
Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201)Karim El-Sahwi, Stefania Bellone, Emiliano Cocco, et al.
British Journal of Cancer|June 19, 2009
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancerE Cocco, S Bellone, K El-Sahwi, et al.
Breast Cancer Research : BCR|November 22, 2018
Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settingsAstrid O Leech, Sri HariKrishna Vellanki, Emily J Rutherford, et al.
Placenta|December 5, 2012
IFPA Meeting 2012 Workshop Report I: comparative placentation and animal models, advanced techniques in placental histopathology, human pluripotent stem cells as a model for trophoblast differentiationW E Ackerman, A M Carter, A M De Mestre, et al.
Pageof 61

Showing results (551-560 of 603) with videos related to

Sort By:
Pageof 61
British Journal of Cancer|August 12, 2010
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinomaE Cocco, Z Hu, C E Richter, et al.
International Journal of Cancer|August 30, 2021
Comparison of liver cancer incidence and survival by subtypes across seven high-income countriesMark J Rutherford, Melina Arnold, Aude Bardot, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|June 22, 2021
Case-ascertainment of acute myocardial infarction hospitalizations in cancer patients: a cohort study using English linked electronic health dataBriana Coles, Lucy Teece, Clive Weston, et al.
Clinical & Experimental Metastasis|July 5, 2011
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factorEmiliano Cocco, Joyce Varughese, Natalia Buza, et al.
Neurobiology of Aging|May 3, 2013
Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUSThomas A Ravenscroft, Matt C Baker, Nicola J Rutherford, et al.
British Journal of Cancer|November 19, 2009
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinomaK El-Sahwi, S Bellone, E Cocco, et al.
Molecular Cancer Therapeutics|January 8, 2010
Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201)Karim El-Sahwi, Stefania Bellone, Emiliano Cocco, et al.
British Journal of Cancer|June 19, 2009
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancerE Cocco, S Bellone, K El-Sahwi, et al.
Breast Cancer Research : BCR|November 22, 2018
Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settingsAstrid O Leech, Sri HariKrishna Vellanki, Emily J Rutherford, et al.
Placenta|December 5, 2012
IFPA Meeting 2012 Workshop Report I: comparative placentation and animal models, advanced techniques in placental histopathology, human pluripotent stem cells as a model for trophoblast differentiationW E Ackerman, A M Carter, A M De Mestre, et al.
Pageof 61